Head to Head Survey: Apricus Biosciences (APRI) and Eyegate Pharmaceuticals (EYEG)
Apricus Biosciences (NASDAQ: APRI) and Eyegate Pharmaceuticals (NASDAQ:EYEG) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.
Risk & Volatility
Apricus Biosciences has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Eyegate Pharmaceuticals has a beta of 3.24, suggesting that its stock price is 224% more volatile than the S&P 500.
This is a breakdown of recent recommendations and price targets for Apricus Biosciences and Eyegate Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Apricus Biosciences presently has a consensus price target of $4.50, suggesting a potential upside of 188.46%. Eyegate Pharmaceuticals has a consensus price target of $7.33, suggesting a potential upside of 543.27%. Given Eyegate Pharmaceuticals’ higher possible upside, analysts plainly believe Eyegate Pharmaceuticals is more favorable than Apricus Biosciences.
Insider & Institutional Ownership
15.3% of Apricus Biosciences shares are held by institutional investors. Comparatively, 13.0% of Eyegate Pharmaceuticals shares are held by institutional investors. 3.6% of Apricus Biosciences shares are held by company insiders. Comparatively, 24.6% of Eyegate Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Apricus Biosciences and Eyegate Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Apricus Biosciences||$5.76 million||3.46||-$10.05 million||$0.68||2.29|
|Eyegate Pharmaceuticals||$767,481.00||25.55||-$13.31 million||($1.30)||-0.88|
Apricus Biosciences has higher revenue and earnings than Eyegate Pharmaceuticals. Eyegate Pharmaceuticals is trading at a lower price-to-earnings ratio than Apricus Biosciences, indicating that it is currently the more affordable of the two stocks.
This table compares Apricus Biosciences and Eyegate Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Apricus Biosciences beats Eyegate Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
Apricus Biosciences Company Profile
Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud’s phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.
Eyegate Pharmaceuticals Company Profile
Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
Receive News & Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.